Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Small Cell Lung Cancer

OncoTree code SCLC · 7 articles

Clinical · Molecular biology

Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation

Gavarró LM, Chen MF, Villalonga ÁQ, et al.

Science translational medicine

This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.

Clinical · Molecular biology

Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer

Fialkoff G, Takahashi N, Sharkia I, et al.

The Journal of clinical investigation

This study investigates the use of plasma nucleosome profiling (cfChIP-seq) to assess tumor burden and molecular subtypes in small cell lung cancer (SCLC). Researchers applied this technique to 441 plasma samples, integrating the profiles with matched tumor transcriptomes. The results demonstrate that cfChIP-seq captures the epigenetic and transcriptional landscape of SCLC, enabling non-invasive inference of transcriptional subtypes. A cfChIP-seq-derived score also tracked radiographic tumor burden and was associated with prognosis. This liquid biopsy platform offers potential for real-time monitoring and therapeutic stratification in SCLC.

Clinical · Molecular biology · Bioinfo & AI

Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer

Yu H, Li M, Li X, et al.

Journal of translational medicine

This study investigated the transcriptomic profile and therapeutic opportunities in EGFR-mutant non-small cell lung adenocarcinoma (LUAD) that undergoes lineage transformation to small cell lung cancer (SCLC), a mechanism of acquired resistance to EGFR TKIs. By analyzing paired pre- and post-transformation samples from 32 patients, researchers characterized the immune microenvironment of transformed SCLC (T-SCLC). They found that T-SCLC exhibits an immunosuppressive microenvironment compared to EGFR-mutant LUAD, yet a more immunologically active one than primary SCLC. Patients with T-SCLC treated with first-line immunotherapy plus chemotherapy showed a median progression-free survival of 5.1 months and a median overall survival of 21.0 months. Immunotherapy exposure was associated with significantly longer overall survival, supporting the integration of immunotherapy in T-SCLC treatment.

Clinical

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

Demir N, Kıkılı Cİ, Kemik F, et al.

Lung cancer (Amsterdam, Netherlands)

This multicenter real-world study investigated histologic transformation to small-cell lung cancer (SCLC) in EGFR-mutant non-small cell lung cancer (NSCLC) patients, an aggressive resistance mechanism to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The study included 59 patients and found that adding immunotherapy (atezolizumab, durvalumab) to carboplatin and etoposide (CE) after transformation was associated with significantly improved post-transformation overall survival (17.0 months versus 9.0 months with CE alone). These findings suggest that immunotherapy may be beneficial in this setting, challenging prior evidence. Systematic re-biopsy is highlighted as crucial to confirm transformation and guide treatment.

Clinical · Molecular biology · Bioinfo & AI

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy

Zhao Y, Wang Q, Xiao B, et al.

Journal for immunotherapy of cancer

This phase II study investigated the efficacy and safety of durvalumab plus olaparib as maintenance therapy in 60 previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The combination regimen demonstrated promising efficacy, with a 12-month progression-free survival rate of 25.0%, a median progression-free survival of 6.8 months, and a median overall survival of 14.6 months. Multi-omics analysis identified a DNA hypomethylation subgroup associated with significantly improved survival outcomes. This subgroup exhibited enhanced antigen presentation, a favorable cytokine profile, and suppressed DNA damage repair pathways, suggesting a potential biomarker for patient selection.

Clinical · Molecular biology

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis

Gao R, Li Z, Huang J, et al.

Lung cancer (Amsterdam, Netherlands)

This multicenter retrospective study analyzed 163 patients with transformed small-cell lung cancer (T-SCLC), a recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. The study aimed to identify early predictors of histological transformation and evaluate post-transformation treatment outcomes. Researchers found a median transformation time of 25.8 months and a median post-transformation overall survival of 14.2 months in EGFR-mutant patients. A predictive model was developed, incorporating age, RB1/NTRK1 mutations, and secondary EGFR T790M mutation as independent risk factors. Taxane-based regimens emerged as a promising later-line therapeutic option for T-SCLC.

Clinical · Molecular biology · Bioinfo & AI

Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy

Zhang J, Liu Y, Yuan H, et al.

British journal of cancer

This study identified three distinct molecular phenotypes of small cell lung cancer (SCLC): proliferative, iNotch, and infiltrated, characterized by high proliferation, inhibitory Notch signaling, and immune-rich microenvironments, respectively. These phenotypes were reproducible across multiple independent cohorts. Further analysis revealed that a subset of patients within the infiltrated phenotype, exhibiting high ANXA1 expression, resisted immune checkpoint inhibitors (ICIs) due to M2 macrophage polarization and CD8+ T cell suppression. Only ANXA1Low infiltrated patients derived significant benefit from chemotherapy combined with ICIs. These findings offer new strategies to enhance immunotherapy efficacy in SCLC.